2 results
Search Results
Now showing 1 - 2 of 2
Article Citation - WoS: 12Citation - Scopus: 14The Results of Sglt-2 Inhibitors Use in Kidney Transplantation: 1-Year Experiences From Two Centers(Springer, 2023) Demir, Mehmet Emin; Ozler, Tuba Elif; Merhametsiz, Ozgur; Sozener, Ulas; Uyar, Murathan; Ercan, Zafer; Turkmen Sariyildiz, GulcinPurposeSodium-glucose co-transporter-2 inhibitor (SGLT-2i) administration is associated with some concerns in regard to the increased risk of genital and urinary tract infections (UTI) in kidney transplant recipients (KTR). In this study, we present the results of SGLT-2i use in KTR, including the early post-transplant period.MethodsParticipants were divided into two groups: SGLT-2i-free diabetic KTR (Group 1, n = 21) and diabetic KTR using SGLT-2i (Group 2, n = 36). Group 2 was further divided into two subgroups according to the posttransplant prescription day of SGLT-2i; < 3 months (Group 2a) and >= 3 months (Group 2b). Groups were compared for development of genital and urinary tract infections, glycated hemoglobin a1c (HgbA1c), estimated glomerular filtration rate (eGFR), proteinuria, weight change, and acute rejection rate during 12-month follow-up.ResultsUrinary tract infections prevalence was 21.1% and UTI-related hospitalization rate was 10.5% in our cohort. Prevalence of UTI and UTI-related hospitalization, eGFR, HgbA1c levels, and weight gain were similar between the SGLT-2i group and SGLT-2i-free group, at the 12-month follow-up. UTI prevalence was similar between groups 2a and 2b (p = 0.871). No case of genital infection was recorded. Significant proteinuria reduction was observed in Group 2 (p = 0.008). Acute rejection rate was higher in the SGLT-2i-free group (p = 0.040) and had an impact on 12-month follow-up eGFR (p = 0.003).ConclusionSGLT-2i in KTR is not associated with an increased risk of genital infection and UTI in diabetic KTR, even in the early posttransplant period. The use of SGLT-2i reduces proteinuria in KTR and has no adverse effects on allograft function at the 12-month follow-up.Article The Effect of Cerium Oxide on Liver and Kidney in Lower Extremity Ischemia Reperfusion Injury in Streptozotocin -Induced Diabetic Mice(Springernature, 2026) Erel, Selin; Ozdemir, Miray Gozde; Kucuk, Aysegul; Sarikaya, Badegul; Sezen, Saban Cem; Atli, Muharrem; Arslan, MustafaIntroductionIschemia-reperfusion injury (IRI) is a major concern in diabetic patients undergoing vascular procedures, causing significant damage to the liver and kidneys. The purpose of this study was to evaluate the protective effects of cerium oxide on the liver and kidneys of diabetic mice with lower extremity IRI.Materials and MethodsThirty Swiss albino mice were divided into five experimental groups: control (C), control diabetes (D), diabetes with cerium oxide (D-CEO2), diabetes with IRI (D-IRI), and diabetes with IRI treated with cerium oxide (D-IRI-CEO2). Diabetes was induced with streptozotocin (125 mg/kg) and lower-extremity IRI was induced by clamping the infrarenal aorta. Cerium oxide was administered intraperitoneally to the 0.5 mg/kg cerium oxide groups 30 min before ischemia. Liver and kidney tissue samples were subsequently analyzed through biochemical assays measuring the total antioxidant status, total oxidant status, oxidative stress index, and paraoxonase-1, as well as histopathological examinations.ResultsThe D-IRI group exhibited greater liver and kidney damage than the control group. The D-IRI-CeO2 group displayed reduced liver and kidney damage compared to the D-IRI group. In both the D-IRI and D-IRI-CeO2 groups, the total oxidant status, oxidative stress index, and paraoxonase-1 acitivity were higher, whereas the total antioxidant status levels were lower. In the D-IRI-CeO2 group, there was a decrease in total oxidant status, oxidative stress index, and paraoxonase-1, whereas total antioxidant status increased compared to D-IRI.ConclusionIntraperitoneal cerium oxide reduces oxidative stress and mitigates liver and kidney damage in diabetic mice subjected to lower extremity ischemia-reperfusion injury.
